IONS News and Press, Ionis Pharmaceuticals Inc. From 09/27/23

2023-09-27 10:25:40 ET More on Ionis Pharmaceuticals, Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Ionis late-stage rare disease data fails t...

Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease PR Newswire Roche gains exclusive worldwide rights to develop, manufacture and commercialize the investigational medicines discovered by Ionis I...

2023-09-26 15:08:59 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Novartis and Ionis in pact for new cardiovascular therapy AstraZeneca-Ionis deal for eplontersen expands to Latin America S...

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 5.6% on the day to $45.05. Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United State...

2023-09-26 07:26:54 ET More on Ionis Seeking Alpha’s Quant Rating on Ionis Pharmaceuticals Financial information for Ionis Pharmaceuticals Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Novartis and Ionis in pact for...

Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome PR Newswire Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo First study to show ...

2023-09-20 13:03:50 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While many retail investors are keen to discover which securities the big market players are snapping up, sometimes it’s more telling to zero in on the stocks institutional traders are s...

Ionis to host investor and analyst day event PR Newswire Ionis Innovation Day: Discovering, Developing and Delivering Transformational Medicines Presentations by key members of Ionis leadership and notable KOLs CARLSBAD, Calif. , Sept. 12, 2023 ...

2023-09-07 03:39:24 ET Summary Ionis Pharmaceuticals is a pioneering drug developer with a focus on antisense technology. The company has successfully developed four commercially approved drugs for various diseases. Ionis has a strong pipeline of late-stage candidates, includi...

2023-08-30 13:42:43 ET Summary Tweedy, Browne's 13F portfolio value increased by 4% to $1.91B, with 46 holdings. Berkshire Hathaway is the largest position at 22% of the portfolio, followed by Alphabet, Johnson & Johnson, Coca-Cola FEMSA, and Ionis Pharma. New stakes inclu...